DENALI THERAPEUTICS INC (DNLI)
US24823R1059 - Common Stock
Oversold Conditions For Denali Therapeutics (DNLI)
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious list of the World's Most Innovative...
To the Moon and Beyond: 7 Stocks With Cosmic Potential
With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential.
Denali spikes after $500M private placement (NASDAQ:DNLI)
Denali Therapeutics (DNLI) stock rises amid plans to raise $500M through a private placement. Read more here.
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad...
Denali Therapeutics Announces $500 million Private Placement Equity Financing
Denali Therapeutics Announces $500 million Private Placement Equity Financing
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad...
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month.
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
New data show additional improvement and stabilization in clinical outcomes in MPS II with 104 weeks of tividenofusp alfa (DNL310) treatment in the...
RSI Alert: Denali Therapeutics (DNLI) Now Oversold
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad...
Interesting DNLI Put And Call Options For September 20th
DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture,...
Flagship Pioneering Debuts Enabling Technologies Initiative
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced the formation of a new strategic initiative to foster enabling...
Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Samsung today announced a collaboration aimed at fostering cutting-edge...
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
Biotech stocks targeting longevity could uncover the fountain of youth in coming years, offering a prime investment opportunity today.
First Week of DNLI February 2024 Options Trading
Citi starts Denali at buy, sees catalyst-rich window starting in 2024 (NASDAQ:DNLI)
Citi has initiated coverage of Denali (DNLI) with a buy rating, citing its deep pipeline, strong science, low valuation and upcoming catalysts. Read more here.
Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in...
JP Morgan bullish on six Big Biotechs, rates nine others neutral or lower (NASDAQ:INSM)
JP Morgan said it was bullish on Insmed (INSM), Denali (DNLI), Immunocore (IMCR), Crinetics (CRNX), Mirum (MIRM) and BioCryst (BCRX), rating all as overweight. Read more here.
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study...
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad...
Commit To Buy Denali Therapeutics At $17.50, Earn 16.2% Annualized Using Options
Flagship Pioneering Launches Pioneering Intelligence
/PRNewswire/ -- Flagship Pioneering today launched Pioneering Intelligence, an initiative of Flagship Pioneering harnessing artificial intelligence (AI) to...
Oversold Conditions For Denali Therapeutics (DNLI)
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines
/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...